Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 328

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Open access
Gauthier, Jordan, Hirayama, Alexandre V., Purushe, Janaki, Hay, Kevin A., Lymp, James, Li, Daniel H., Yeung, Cecilia C. S., Sheih, Alyssa, Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Phi, Tinh-Doan, Steinmetz, Rachel N., Shadman, Mazyar, Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.·2020·Blood

Abstract

We previously reported durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) patients treated with CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T-cell immunotherapy after ibrutinib failure. Because preclinical studies showed that ibrutinib could improve CAR T cell-antitumor efficacy and reduce cytokine release syndrome (CRS), we conducted a pilot study to evaluate the safety and feasibility of administering ibrutinib concurrently with CD19 CAR T-cell immunotherapy. Nineteen CLL patients were included. The median number of prior therapies was 5, and 17 patients (89%) had high-risk cytogenetics (17p deletion and/or complex karyotype). Ibrutinib was scheduled to begin ≥2 weeks before leukapheresis and continue for ≥3 months after CAR T-cell infusion. CD19 CAR T-cell therapy with concurrent ibrutinib was well tolerated; 13 patients (68%) received ibrutinib as planned without dose reduction. The 4-week overall response rate using 2018 International Workshop on CLL (iwCLL) criteria was 83%, and 61% achieved a minimal residual disease (MRD)-negative marrow response by IGH sequencing. In this subset, the 1-year overall survival and progression-free survival (PFS) probabilities were 86% and 59%, respectively. Compared with CLL patients treated with CAR T cells without ibrutinib, CAR T cells with concurrent ibrutinib were associated with lower CRS severity and lower serum concentrations of CRS-associated cytokines, despite equivalent in vivo CAR T-cell expansion. The 1-year PFS probabilities in all evaluable patients were 38% and 50% after CD19 CAR T-cell therapy, with and without concurrent ibrutinib, respectively (P = .91). CD19 CAR T cells with concurrent ibrutinib for R/R CLL were well tolerated, with low CRS severity, and led to high rates of MRD-negative response by IGH sequencing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2019002936

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 328

Metadata

Authors
Gauthier, J., Hirayama, A. V., Purushe, J., Hay, K. A., Lymp, J., Li, D. H., Yeung, C. C. S., Sheih, A., Pender, B. S., Hawkins, R. M., Vakil, A., Phi, T.-D., Steinmetz, R. N., Shadman, M., Riddell, S. R., Maloney, D. G., & Turtle, C. J.
Venue
Blood
Published
2020-05-07
Volume
135
Issue
19
Pages
1650-1660
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3007925874
Cited by
328
References
39
FWCI
25.03
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. https://app.cochat.ai/papers/10.1182/blood.2019002936
The paper
Gauthier, J., Hirayama, A. V., Purushe, J., Hay, K. A., Lymp, J., Li, D. H., Yeung, C. C. S., Sheih, A., Pender, B. S., Hawkins, R. M., Vakil, A., Phi, T.-D., Steinmetz, R. N., Shadman, M., Riddell, S. R., Maloney, D. G., & Turtle, C. J. (2020). Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. https://doi.org/10.1182/blood.2019002936

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.